Beractant

贝雷克坦

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBeractant
Drug Alias Name贝拉克坦贝拉康坦SurvantaSurfactenA-60386X
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsInfant, Newborn, DiseasesPremature BirthRetinopathy of Prematurity +[7] 
Global Approved IndicationsRespiratory Distress Syndrome, Newborn
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1991/07/01
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesFuji Pharma Co LtdAbbvie Inc
Inactive CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentPostgraduate Institute Of Medical Education And ResearchAll India Institute Of Medical Sciences, New Delhi +[6] 
Active IndicationsRespiratory Distress Syndrome, Newborn
Inactive IndicationsInfant, Newborn, DiseasesPremature BirthRetinopathy of Prematurity +[6] 

Other Information

ATC CodeR07AA02
Related LinksWikipediaDrugBankKEGG